US4737487A
Expired / Lapsed
US
⏱️ 0.0 years remaining
VIP type peptides
Assignee: Beecham Group PLC
•
Filing: 1985-10-31
•
Granted: 1988-04-12
•
Expires: 2005-10-31
Abstract
Abstract Peptides comprising, in sequence, units selected from the amino acid residues 11 to 23 of vasoactive intestinal peptide (VIP) and consisting at least of the amino acid residues 15 to 20, or an analogue thereof wherein one or more of the amino acid residues is replaced by an equivalent other amino acid, or a pharmaceutically acceptable salt thereof; having pharmacological activity, a process for their preparation and their use as pharmaceuticals.
Inventors
- 👤 Eric A. Watts
- 👤 Gordon Wootton
- 👤 Christine Summers
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 07:12
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/57563; A; A61; A61P; A61P11/00; A61P11/08; A61P9/00; A61P9/08; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/17
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
292 words
A polypeptide of the general formula X--(Y').sub.n --Y.sub.15 Y.sub.16 Y.sub.17 Y.sub.18 Y.sub.19 Y.sub.20 --(Y").sub.m --Z in which X represents a hydrogen atom or an amine-protecting group, preferably a hydrogen atom; (Y') n represents a direct bond or Y.sub.11 Y.sub.12 Y.sub.13 Y.sub.14, Y.sub.12 Y.sub.13 Y.sub.14, Y.sub.13 Y.sub.14 or Y.sub.14 in which Y 11 represents Thr, Ser or the residue of another naturally occurring hydroxy amino acid, Y 12 represents Arg or the residue of another naturally occurring basic amino acid, Y 13 represents Leu, Phe or the residue of another naturally occurring hydrophobic amino acid, Y 14 represents Arg or the residue of another naturally occurring basic amino acid; Y 15 represents Lys or the residue of another naturally occurring basic amino acid, Y 16 represents Gln or the residue of another naturally occurring carboxamido amino acid, Y 17 represents Met or the residue of another naturally occurring neutral amino acid, Y 18 represents Ala or the residue of another naturally occurring hydrophobic amino acid, Y 19 represents Val or the residue of another naturally occurring hydrophobic amino acid, Y 20 represents Lys or the residue of another basic naturally occurring amino acid, (Y") m represents a direct bond or Y.sub.21, Y.sub.21 Y.sub.22 or Y.sub.21 Y.sub.22 Y.sub.23 in which Y 21 represents Lys or the residue of another basic naturally occurring amino acid, Y 22 represents Tyr or the residue of another naturally occurring hydrophobic amino acid, Y 23 represents Leu or the residue of another naturally occurring hydrophobic amino acid; and Z represents a hydroxyl group, or a group of the formula OR such COZ represents an ester, or a hydrazino group such that COZ represents a hydrazide, or NH 2 such that COZ represents an amide; and pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim
292 words
A polypeptide of the general formula X--(Y').sub.n --Y.sub.15 Y.sub.16 Y.sub.17 Y.sub.18 Y.sub.19 Y.sub.20 --(Y").sub.m --Z in which X represents a hydrogen atom or an amine-protecting group, preferably a hydrogen atom; (Y') n represents a direct bond or Y.sub.11 Y.sub.12 Y.sub.13 Y.sub.14, Y.sub.12 Y.sub.13 Y.sub.14, Y.sub.13 Y.sub.14 or Y.sub.14 in which Y 11 represents Thr, Ser or the residue of another naturally occurring hydroxy amino acid, Y 12 represents Arg or the residue of another naturally occurring basic amino acid, Y 13 represents Leu, Phe or the residue of another naturally occurring hydrophobic amino acid, Y 14 represents Arg or the residue of another naturally occurring basic amino acid; Y 15 represents Lys or the residue of another naturally occurring basic amino acid, Y 16 represents Gln or the residue of another naturally occurring carboxamido amino acid, Y 17 represents Met or the residue of another naturally occurring neutral amino acid, Y 18 represents Ala or the residue of another naturally occurring hydrophobic amino acid, Y 19 represents Val or the residue of another naturally occurring hydrophobic amino acid, Y 20 represents Lys or the residue of another basic naturally occurring amino acid, (Y") m represents a direct bond or Y.sub.21, Y.sub.21 Y.sub.22 or Y.sub.21 Y.sub.22 Y.sub.23 in which Y 21 represents Lys or the residue of another basic naturally occurring amino acid, Y 22 represents Tyr or the residue of another naturally occurring hydrophobic amino acid, Y 23 represents Leu or the residue of another naturally occurring hydrophobic amino acid; and Z represents a hydroxyl group, or a group of the formula OR such COZ represents an ester, or a hydrazino group such that COZ represents a hydrazide, or NH 2 such that COZ represents an amide; and pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
16 words
A peptide according to claim 1 wherein all the amino acid units are in the L-form.
Claim 4
Dependent Claim
24 words
A peptide or analogue according to claim 1 wherein the carboxy-terminus of the peptide or analogue is in the form of the unsubstituted amide.
Claim 5
Dependent Claim
22 words
A peptide or analogue according to claim 1 wherein the amino-terminus of the peptide is in the form of the unsubstituted amine.
Claim 6
Dependent Claim
14 words
The hexapeptide H-Lys-Gln-Y-Ala-Val-Lys-NH 2 or H-Lys-Gln-Y-Ala-Leu-Lys-NH 2 , wherein Y represents Met or Nle.
Claim 7
Dependent Claim
14 words
The hexapeptide H-Lys-Gln-Y-Ala-Val-Lys-NH 2 or H-Lys-Gln-Y-Ala-Leu-Lys-NH 2 , wherein Y represents Met or Nle.
Claim 8
Dependent Claim
44 words
H-Lys-Gln-Nle-Ala-Val-Lys-NH 2 , H-Arg-Lys-Gln-Nle-Ala-Val-Lys-Lys-NH 2 , H-Leu-Arg-Lys-Gln-Nle-Ala-Val-Lys-Lys-NH 2 , H-Lys-Gln-Nle-Ala-Leu-Lys-NH 2 , H-Lys-Gln-Nle-Ala-Val-Orn-NH 2 , H-Orn-Gln-Nle-Ala-Val-Orn-NH 2 , H-Lys-Gln-Leu-Ala-Val-Lys-NH 2 , H-Arg-Lys-Gln-Nle-Ala-Val-Lys-Lys-Tyr-Leu-NH 2 , H-Lys-Gln-Nle-Ala-Val-Lys-Lys-Tyr-Leu-NH 2 , H-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-NH 2 , H-Lys-Gln-Nle-Ala-Val-Lys-Lys-NH 2 or ##STR9## or a pharmaceutically acceptable salt of any of the foregoing.
Claim 9
Dependent Claim
44 words
H-Lys-Gln-Nle-Ala-Val-Lys-NH 2 , H-Arg-Lys-Gln-Nle-Ala-Val-Lys-Lys-NH 2 , H-Leu-Arg-Lys-Gln-Nle-Ala-Val-Lys-Lys-NH 2 , H-Lys-Gln-Nle-Ala-Leu-Lys-NH 2 , H-Lys-Gln-Nle-Ala-Val-Orn-NH 2 , H-Orn-Gln-Nle-Ala-Val-Orn-NH 2 , H-Lys-Gln-Leu-Ala-Val-Lys-NH 2 , H-Arg-Lys-Gln-Nle-Ala-Val-Lys-Lys-Tyr-Leu-NH 2 , H-Lys-Gln-Nle-Ala-Val-Lys-Lys-Tyr-Leu-NH 2 , H-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-NH 2 , H-Lys-Gln-Nle-Ala-Val-Lys-Lys-NH 2 or ##STR9## or a pharmaceutically acceptable salt of any of the foregoing.
Claim 10
Dependent Claim
10 words
A compound according to claim 1 in pharmaceutically acceptable form.
Claim 11
Dependent Claim
32 words
A pharmaceutical composition for treating peptic ulcer disease comprising an effective amount of a peptide or analogue according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim
37 words
A method of treatment of peptic ulcer disease disorders in mammals, such as humans which comprises the administration of an effective amount of a peptide or analogue according to claim 1, or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-04-12 | 1991-10-12 | 1992-04-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-04-12 | 1995-10-12 | 1996-04-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-04-12 | 1999-10-12 | 2000-04-12 | $7700.00 | Window Closed / Lapsed |